Odyssey Therapeutics (ODTX) FDA Approvals $16.94 -1.40 (-7.63%) As of 03:59 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Odyssey Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Odyssey Therapeutics (ODTX). Over the past two years, Odyssey Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as OD-001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. OD-001 FDA Regulatory Timeline and Events OD-001 is a drug developed by Odyssey Therapeutics for the following indication: in Ulcerative Colitis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Results - October 20,2026Results Drug: OD-001Announced Date: October 20, 2026Indication: in Ulcerative ColitisAnnouncementOdyssey Therapeutics, Inc. announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).AI SummaryOdyssey Therapeutics reported results from the 12-week induction period of its Phase 2a trial of oral OD-001 in moderate-to-severe ulcerative colitis. Among 56 evaluable patients, the study met its primary goal: the modified Mayo score fell by an average of 2.4 points (p<0.001). At the 20 mg twice-daily dose, 27% of patients achieved clinical remission, 61% had a clinical response, and 49% reached symptomatic remission. Symptom relief began early and continued to improve through Week 12. Clinical improvements were associated with changes in inflammatory blood and stool markers, biopsy-based gene activity, and tissue disease measures. These findings support the drug’s proposed action on RIPK2 and point to 20 mg twice daily as a potential effective dose. OD-001 was generally well tolerated, with no serious adverse events or treatment-related discontinuations reported. Because the trial was open-label and had no placebo group, results need confirmation. Odyssey plans controlled trials of OD-001 alone and with vedolizumab.Read AnnouncementProvided Update - October 12,2026Provided Update Drug: OD-001Announced Date: October 12, 2026Indication: in Ulcerative ColitisAnnouncementOdyssey Therapeutics, Inc. announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee.AI SummaryOdyssey Therapeutics will present the design of a Phase 2a trial testing OD-001 with vedolizumab in people with moderate-to-severe ulcerative colitis at the American College of Gastroenterology’s 2026 Annual Scientific Meeting in Nashville, October 9–14. The randomized, double-blind, placebo-controlled study is the first clinical trial in ulcerative colitis to combine treatments aimed at both innate and adaptive immune responses. OD-001 blocks RIPK2, a protein involved in early immune activation, while vedolizumab limits immune cells from moving into the gut. The study is expected to enroll up to 146 patients worldwide. Participants will receive the combination for a 12-week induction period, then continue maintenance treatment with OD-001 alone through Week 52. Odyssey expects to report initial induction results in the second half of 2027. The poster will be presented on October 13 by Dr. Bruce Sands.Read AnnouncementResults - October 6,2026Results Phase 2aDrug: OD-001Announced Date: October 6, 2026Indication: in Ulcerative ColitisAnnouncementOdyssey Therapeutics, Inc. announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at United European Gastroenterology (UEG) Week 2026, taking place October 17-20, in Barcelona, Spain.AI SummaryOdyssey Therapeutics announced that additional results from the induction period of its Phase 2a trial of OD-001 in people with moderate to severe ulcerative colitis will be presented at UEG Week 2026 in Barcelona, October 17–20. The oral presentation, titled “Safety and Efficacy of OD-001,” is scheduled for Tuesday, October 20, at 9:00 a.m. CEST (3:00 a.m. EDT). It will be presented by Dr. Bruce Sands and is listed as presentation OP197 in the UEG Forum. OD-001 is described as a first-in-class oral RIPK2 scaffolding inhibitor. Odyssey will hold a conference call and webcast at 8:00 a.m. EDT that day to discuss additional trial data beyond what is presented at UEG Week. The live webcast will be available in the News and Events section of the company’s website, and a replay will be posted for 180 days. The announcement did not disclose the trial’s safety or efficacy results.Read Announcement Odyssey Therapeutics FDA Events - Frequently Asked Questions Has Odyssey Therapeutics received FDA approval? As of now, Odyssey Therapeutics (ODTX) has not received any FDA approvals for its therapy in the last two years. What drugs has Odyssey Therapeutics submitted to the FDA? In the past two years, Odyssey Therapeutics (ODTX) has reported FDA regulatory activity for OD-001. What is the most recent FDA event for Odyssey Therapeutics? The most recent FDA-related event for Odyssey Therapeutics occurred on October 20, 2026, involving OD-001. The update was categorized as "Results," with the company reporting: "Odyssey Therapeutics, Inc. announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis (UC)." What conditions do Odyssey Therapeutics' current drugs treat? Currently, Odyssey Therapeutics has one therapy (OD-001) targeting the following condition: in Ulcerative Colitis. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Belite Bio FDA EventsErasca FDA EventsGilead Sciences FDA EventsNuCana FDA EventsUnited Therapeutics FDA EventsAdagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Amylyx Pharmaceuticals FDA Events AbCellera Biologics FDA Events Legend Biotech FDA Events Iovance Biotherapeutics FDA Events Viking Therapeutics FDA Events Viridian Therapeutics FDA Events Parabilis Medicines FDA Events Zai Lab FDA Events Dyne Therapeutics FDA Events Celcuity FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:ODTX last updated on 10/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | SponsoredWashington's deadline. Elon's problem.On January 1, 2027, Washington raises the outside-China sourcing requirement for grid battery projects seeking...Behind the Markets | SponsoredThe One-Ticker Retirement BoostA $10,000 investment at its 1998 start would be worth over $630,000 today, roughly 6X the S&P 500 over the sam...The Oxford Club | SponsoredShould I sell? $84 off ends Dec 9A stock you own drops 20%, and you're asking yourself: should I sell? Seeking Alpha Premium gives you a second...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Odyssey Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Odyssey Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Results - October 20,2026Results Drug: OD-001Announced Date: October 20, 2026Indication: in Ulcerative ColitisAnnouncementOdyssey Therapeutics, Inc. announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).AI SummaryOdyssey Therapeutics reported results from the 12-week induction period of its Phase 2a trial of oral OD-001 in moderate-to-severe ulcerative colitis. Among 56 evaluable patients, the study met its primary goal: the modified Mayo score fell by an average of 2.4 points (p<0.001). At the 20 mg twice-daily dose, 27% of patients achieved clinical remission, 61% had a clinical response, and 49% reached symptomatic remission. Symptom relief began early and continued to improve through Week 12. Clinical improvements were associated with changes in inflammatory blood and stool markers, biopsy-based gene activity, and tissue disease measures. These findings support the drug’s proposed action on RIPK2 and point to 20 mg twice daily as a potential effective dose. OD-001 was generally well tolerated, with no serious adverse events or treatment-related discontinuations reported. Because the trial was open-label and had no placebo group, results need confirmation. Odyssey plans controlled trials of OD-001 alone and with vedolizumab.Read Announcement
Provided Update - October 12,2026Provided Update Drug: OD-001Announced Date: October 12, 2026Indication: in Ulcerative ColitisAnnouncementOdyssey Therapeutics, Inc. announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee.AI SummaryOdyssey Therapeutics will present the design of a Phase 2a trial testing OD-001 with vedolizumab in people with moderate-to-severe ulcerative colitis at the American College of Gastroenterology’s 2026 Annual Scientific Meeting in Nashville, October 9–14. The randomized, double-blind, placebo-controlled study is the first clinical trial in ulcerative colitis to combine treatments aimed at both innate and adaptive immune responses. OD-001 blocks RIPK2, a protein involved in early immune activation, while vedolizumab limits immune cells from moving into the gut. The study is expected to enroll up to 146 patients worldwide. Participants will receive the combination for a 12-week induction period, then continue maintenance treatment with OD-001 alone through Week 52. Odyssey expects to report initial induction results in the second half of 2027. The poster will be presented on October 13 by Dr. Bruce Sands.Read Announcement
Results - October 6,2026Results Phase 2aDrug: OD-001Announced Date: October 6, 2026Indication: in Ulcerative ColitisAnnouncementOdyssey Therapeutics, Inc. announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at United European Gastroenterology (UEG) Week 2026, taking place October 17-20, in Barcelona, Spain.AI SummaryOdyssey Therapeutics announced that additional results from the induction period of its Phase 2a trial of OD-001 in people with moderate to severe ulcerative colitis will be presented at UEG Week 2026 in Barcelona, October 17–20. The oral presentation, titled “Safety and Efficacy of OD-001,” is scheduled for Tuesday, October 20, at 9:00 a.m. CEST (3:00 a.m. EDT). It will be presented by Dr. Bruce Sands and is listed as presentation OP197 in the UEG Forum. OD-001 is described as a first-in-class oral RIPK2 scaffolding inhibitor. Odyssey will hold a conference call and webcast at 8:00 a.m. EDT that day to discuss additional trial data beyond what is presented at UEG Week. The live webcast will be available in the News and Events section of the company’s website, and a replay will be posted for 180 days. The announcement did not disclose the trial’s safety or efficacy results.Read Announcement